SCHEMBL1375089

SCHEMBL1375089

COC(=O)c1ccc(-c2ccc(C(N)=O)cc2)cc1OCc1cccc2ccccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP10 Q53GL7 4/20 0.61
▸ FDPS P14324 1/20 0.60
▸ PARP15 Q460N3 2/20 0.58
▸ MEN1 O00255 5/20 0.55
▸ KMT2A Q03164 5/20 0.55
▸ MAPK8 P45983 3/20 0.46
▸ MAPK9 P45984 3/20 0.46
▸ MAPK10 P53779 3/20 0.46
▸ MCL1 Q07820 1/20 0.44
▸ PDE4A P27815 1/20 0.43
▸ PDE4B Q07343 1/20 0.43
▸ PDE4C Q08493 1/20 0.43
▸ PDE4D Q08499 1/20 0.43
▸ ADAMTS4 O75173 1/20 0.42
▸ MMP13 P45452 1/20 0.42
▸ MTNR1A P48039 1/20 0.41
▸ MTNR1B P49286 1/20 0.41
▸ MAOB P27338 1/20 0.40
▸ PARP14 Q460N5 1/20 0.40
▸ ALDH1A1 P00352 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1375324 0.88 FDPS (0.69) PARP10FDPSPARP15MEN1KMT2A
SCHEMBL27861628 0.81 FDPS (0.62) PARP10FDPSPARP15MEN1KMT2A
SCHEMBL1376902 0.80 PARP10 (0.56) PARP10FDPSPARP15MEN1KMT2A
SCHEMBL1378315 0.79 FDPS (0.78) PARP10FDPSPARP15MEN1KMT2A
SCHEMBL12149587 0.78 FDPS (0.70) PARP10FDPSPARP15MEN1KMT2A
SCHEMBL7910959 0.78 PARP10 (0.64) PARP10FDPSPARP15MEN1KMT2A
SCHEMBL12149699 0.77 FDPS (0.74) PARP10FDPSPARP15MEN1KMT2A
SCHEMBL7911237 0.75 PARP10 (0.64) PARP10FDPSPARP15MEN1KMT2A
SCHEMBL12149707 0.75 FDPS (1.00) PARP10FDPSPARP15MEN1KMT2A
SCHEMBL12149679 0.75 FDPS (0.72) PARP10FDPSPARP15MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110288057-A1 SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS NOVARTIS AG (CH) 2011-11-24 — — US disclosed
EP-2342173-A1 SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS Novartis AG (CH) 2011-07-13 — — EP disclosed
WO-2010043584-A1 SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS NOVARTIS AG (CH) 2010-04-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288057-A1 SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS FDPS, GGPS1, COASY PARP10 1018/4885FDPS 1/4885PARP15 521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback